Patents by Inventor Darrell Pilling

Darrell Pilling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230226088
    Abstract: The present disclosure relates to methods of treating Coronavirus-Associated Lung Damage (CALD) and cytokine storm using CALD-treating compounds. The methods can involve administering CALD-treating compounds to a patient suffering from CALD or cytokine storm.
    Type: Application
    Filed: June 7, 2021
    Publication date: July 20, 2023
    Applicant: The Texas A&M University System
    Inventors: Richard H. GOMER, Darrell PILLING, Tejas KARHADKAR
  • Publication number: 20230218718
    Abstract: The present disclosure relates to methods of treating Coronavirus-Associated Lung Damage (CALD) and cytokine storm using CALD-treating polypeptides. The methods can involve administering serum amyloid P-component to a patient suffering from CALD or cytokine storm.
    Type: Application
    Filed: June 7, 2021
    Publication date: July 13, 2023
    Applicant: The Texas A&M University System
    Inventors: Richard H. GOMER, Darrell PILLING, Tejas KARHADKAR
  • Publication number: 20220133671
    Abstract: The present disclosure relates to methods of preventing or inhibiting fibrosis using small molecule sialidase inhibitors. The present disclosure also relates to methods treating obesity, liver inflammation, steatosis, and cancer. These methods can involve administering the compounds to a patent at risk of developing fibrosis inflammation, obesity, steatosis, or cancer, in a manner that inhibits NEU3.
    Type: Application
    Filed: February 10, 2020
    Publication date: May 5, 2022
    Applicant: The Texas A&M University System
    Inventors: Richard H. Gomer, Thomas Meek, Tejas Karhadkar, Darrell Pilling
  • Publication number: 20190201485
    Abstract: The present disclosure relates to anti-fibrotic sialidase-inhibitor compounds and methods of preventing or inhibiting fibrosis using such compounds. The present disclosure also relates to methods of controlling the formation of fibrocytes or their activity using such compounds. The compounds may include both antibodies as well as small molecules. The methods may involve administering the compounds to a patient with or at risk of developing fibrosis in a manner that inhibits at least one sialidase in the patient.
    Type: Application
    Filed: March 5, 2019
    Publication date: July 4, 2019
    Inventors: Richard H. Gomer, Darrell Pilling, Nehemiah Cox, Tejas R. Karhadkar
  • Publication number: 20130039897
    Abstract: The disclosure relates to compositions including dipeptidyl peptidase-IV (DPPIV) as well as compositions including an anti-DPPIV antibody operable to bind a DPPIV region structurally homologous to a Dictyostelium autocrine proliferation repressor A (AprA) region. The disclosure also relates to a method of reducing the number of neutrophils in a body region by administering a DPPIV composition to the body region in an amount and for a time sufficient to suppress neutrophil movement into the body region or enhancing neutrophil movement out of the body region. In particular, it relates to a method of reducing the number of neutrophils in a body region suffering from an acute injury or from a chronic or long-term disease. Further, the disclosure relates to a method of increasing the number of neutrophils in a body region by administering an anti-DPPIV antibody operable to bind a DPPIV region structurally homologous to a Dictyostelium AprA region.
    Type: Application
    Filed: August 10, 2012
    Publication date: February 14, 2013
    Applicant: The Texas A&M University System
    Inventors: Richard Gomer, Jonathan Phillips, Sarah Herlihy, Anu S. Maharjan, Darrell Pilling
  • Patent number: 8187608
    Abstract: The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: May 29, 2012
    Assignee: William Marsh Rice University
    Inventors: Richard Gomer, Darrell Pilling
  • Patent number: 8187599
    Abstract: The present invention relates to the ability of anti-Fc?R antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: May 29, 2012
    Assignee: William Marsh Rice University
    Inventors: Richard Gomer, Darrell Pilling
  • Publication number: 20120009146
    Abstract: The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
    Type: Application
    Filed: September 23, 2011
    Publication date: January 12, 2012
    Applicant: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Richard Gomer, Darrell Pilling
  • Publication number: 20110311554
    Abstract: The present invention relates to the ability of anti-Fc?R antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.
    Type: Application
    Filed: September 2, 2011
    Publication date: December 22, 2011
    Inventors: Richard Gomer, Darrell Pilling
  • Patent number: 8057802
    Abstract: The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: November 15, 2011
    Assignee: William Marsh Rice University
    Inventors: Richard Gomer, Darrell Pilling
  • Patent number: 8012472
    Abstract: The present invention relates to the ability of anti-Fc?R antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: September 6, 2011
    Assignee: William Marsh Rice University
    Inventors: Richard Gomer, Darrell Pilling
  • Patent number: 7935682
    Abstract: The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the invention may include assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: May 3, 2011
    Assignee: William Marsh Rice University
    Inventors: Richard Gomer, Darrell Pilling
  • Publication number: 20100297074
    Abstract: The present disclosure relates, according to some embodiments, to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the disclosure may include assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects.
    Type: Application
    Filed: April 9, 2010
    Publication date: November 25, 2010
    Inventors: Richard Hans Gomer, Darrell Pilling
  • Publication number: 20100221208
    Abstract: The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
    Type: Application
    Filed: December 24, 2008
    Publication date: September 2, 2010
    Applicant: William Marsh Rice University
    Inventors: Richard Gomer, Darrell Pilling
  • Patent number: 7763256
    Abstract: The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: July 27, 2010
    Assignee: William Marsh Rice University
    Inventors: Richard Gomer, Darrell Pilling
  • Patent number: 7666432
    Abstract: The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress the differentiation of monocytes into fibrocytes. Methods and compositions for suppressing differentiation of monocytes into fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: February 23, 2010
    Assignee: William Marsh Rice University
    Inventors: Richard Gomer, Darrell Pilling
  • Publication number: 20070065866
    Abstract: The present invention relates to the ability of anti-Fc?R antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.
    Type: Application
    Filed: September 27, 2006
    Publication date: March 22, 2007
    Inventors: Richard Gomer, Darrell Pilling
  • Publication number: 20070065368
    Abstract: The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
    Type: Application
    Filed: September 27, 2006
    Publication date: March 22, 2007
    Inventors: Richard Gomer, Darrell Pilling
  • Publication number: 20060002938
    Abstract: The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the invention may include assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects.
    Type: Application
    Filed: June 22, 2005
    Publication date: January 5, 2006
    Inventors: Richard Gomer, Darrell Pilling
  • Publication number: 20050238620
    Abstract: The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress the differentiation of monocytes into fibrocytes. Methods and compositions for suppressing differentiation of monocytes into fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
    Type: Application
    Filed: June 22, 2005
    Publication date: October 27, 2005
    Inventors: Richard Gomer, Darrell Pilling